Geron Corporation Reports Third Quarter 2020 Financial Results and Current Events
November 05, 2020 16:05 ET
|
Geron Corporation
FOSTER CITY, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the third quarter ended...
Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results
October 19, 2020 14:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
Constellation Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
September 09, 2020 15:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to...
Constellation Pharmaceuticals Announces Second-Quarter 2020 Financial Results, Provides Regulatory Update
August 05, 2020 07:00 ET
|
Constellation Pharmaceuticals , Inc.
Constellation has aligned with the FDA on the design of MANIFEST-2, the pivotal Phase 3 clinical trial for CPI-0610 expected to begin in 2H20Constellation plans to explore additional indications for...
Constellation Pharmaceuticals to Host Conference Call to Discuss Second Quarter 2020 Results
July 31, 2020 12:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
Geron Reports Four Imetelstat Data Presentations at Virtual Edition of the European Hematology Association (EHA) Annual Congress
June 12, 2020 08:30 ET
|
Geron Corporation
For the IMerge Phase 2 clinical trial, meaningful and durable transfusion independence reported with a new 1-year TI rate, indicating potential disease-modifying activity of imetelstat treatmentFor...
Geron Corporation Reports First Quarter 2020 Financial Results
May 28, 2020 16:05 ET
|
Geron Corporation
MENLO PARK, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2020. The Company will host a conference...
Constellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610
May 28, 2020 12:00 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Geron Corporation Announces the Closing of its Public Offering of Common Stock and Warrants
May 27, 2020 16:30 ET
|
Geron Corporation
MENLO PARK, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its previously announced...
Geron Corporation Announces the Pricing of its Public Offering of Common Stock and Warrants
May 22, 2020 07:15 ET
|
Geron Corporation
MENLO PARK, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of its previously announced...